Darbepoetin alfa and chronic kidney disease.
Minnerup
Jens
J
Schäbitz
Wolf-Rüdiger
WR
D000740:Anemia / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000401:mortality; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000150:complications; D020521:Stroke / Q000139:chemically induced / Q000453:epidemiology; D010959:Tissue Plasminogen Activator / Q000009:adverse effects
D006397:Hematinics; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D010959:Tissue Plasminogen Activator